Flesinoxan
Chemical compound
From Wikipedia, the free encyclopedia
Flesinoxan (developmental code name DU-29373) is a potent and selective 5-HT1A receptor partial or near-full agonist of the phenylpiperazine class.[1][2][3][4] Originally developed as a potential antihypertensive drug,[2][3][5] flesinoxan was later found to possess antidepressant and anxiolytic effects in animal tests.[6][7] As a result, it was investigated in several small human pilot studies for the treatment of major depressive disorder, and was found to have robust effectiveness and very good tolerability.[8][9] It was also developed for treatment of anxiety disorders.[1] The drug reached phase 3 clinical trials for anxiety disorders.[1] However, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further.[1][10] In humans, flesinoxan enhances REM sleep latency, decreases body temperature, and increases ACTH, cortisol, prolactin, and growth hormone secretion.[3][9] In addition, both flesinoxan and LY-178210 induce anxiety in humans.[11]
- None
| |
| Clinical data | |
|---|---|
| Other names | DU-29373; DU29373; DU-29,373 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin 5-HT1A receptor agonist |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H26FN3O4 |
| Molar mass | 415.465 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
